Year of investment
Nuformix is a pharmaceutical development company targeting the unmet medical needs in fibrosis and oncology using drug repurposing. They have the ability to develop novel drug forms with improved physical properties and develop new products that are differentiated from the original drug used.
CPI value creation
CPI Enterprises worked collaboratively with the management team to execute a number of strategic initiatives, including the listing on the London Stock Exchange. In 2022, CPI Enterprises realised its investment in Nuformix, a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology, achieved a 14.3x total return on investment.